Introduction
At the ASCO 2010 Annual Meeting, several presented abstracts identified specific biomarkers, EML4-ALK translocation and EGFR mutation, which can be used to select patients for targeted therapies. Trials presented also demonstrated that studies with novel targeted agents are unlikely to be successful in an unselected patient population with advanced non-small cell lung cancer (NSCLC). This newsletter will review the key presentations on NSCLC from ASCO 2010.
Featured Content
• Targeted Agents in Advanced Disease
• Chemotherapy for Advanced Disease
• Negative Trials in Advanced Disease
• Maintenance Therapy in Advanced Disease
• Approaches to Early-Stage NSCLC
• Lung Cancer Prevention
Editors
Corey J. Langer, MD, FACP, bio | Thomas E. Stinchcombe, MD, bio
Media: Newsletter
Estimated time to complete activity: 1.5 hours |
Release date: July 12, 2010 | Expiration date: July 11, 2011
Target Audience
The intended audience for this initiative is medical, surgical, and radiation oncologists, as well as allied oncology healthcare professionals charged with the care of patients with lung cancer.
Learning Objectives
Upon completion of this educational program, participants should be better able to:
- Describe the most current advances for the diagnosis and staging of patients with lung cancer
- Describe the rationale for the development and integration of new therapeutic approaches in lung cancer
- Discuss the clinical implications of the results from pivotal clinical trials that have impacted the use of new approaches and strategies for the treatment of NSCLC
- Review ongoing clinical trial designs of novel surgical, radiotherapeutic, and chemotherapeutic treatment strategies for the management of NSCLC
- Discuss supportive care issues and side effect management required for patients with lung cancer
|
ACCREDITATION INFORMATION
PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Educational Concepts Group, LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
| PHARMACIST CONTINUING EDUCATION |
 |
Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
|
Type of activity: Knowledge-based
Educational Concepts Group, LLC designates this continuing education activity for 1.5 contact hours (0.15 CEUs) (UAN 0199-0000-10-022-H01-P). |
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this activity. During the period July 12, 2010 through July 11, 2011, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-activity assessment.
CME/CE CREDIT
Physicians and pharmacists who complete the post-test with a score of 70% or better may view and print their credit letter or statement of credit via the website, www.educationalconcepts.net.
ECG HAS DECLARED THE FOLLOWING FINANCIAL RELATIONSHIPS
ECG receives educational grants from pharmaceutical industry and other commercial sources. Planners, managers, and other staff members at ECG have no relevant financial relationships to disclose.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.
DISCLOSURE OF OFF-LABEL USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. |
ACKNOWLEDGEMENT
The editors wish to thank Lea Ann Hansen, PharmD, BCOP, a paid employee of ECG, and Jolynn Knoche Sessions, a paid medical writer, for assistance in writing this document.
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Inc./Onyx Pharmaceuticals, Inc.,
Genentech BioOncology & OSI Oncology.
FACULTY DISCLOSURE STATEMENT
All faculty participating in continuing education activities sponsored by ECG are expected to disclose to the audience any real or apparent commercial financial affiliations related to the content of their presentations/materials.
THE FOLLOWING FACULTY MEMBERS HAVE DECLARED RELEVANT FINANCIAL RELATIONSHIPS
Corey J. Langer, MD, FACP
Grants/Research Support
Bristol-Myers Squibb Company, Genentech, Inc, ImClone Systems,
Lilly USA, LLC, OSI Pharmaceuticals, Inc., Pfizer Inc.
Scientific Advisor
Abraxis Bioscience, Abbott Laboratories, Amgen Inc, AstraZeneca,
Bayer HealthCare Pharmaceuticals, Inc./Onyx Pharmaceuticals, Inc.,
Biodesix, Inc., Bristol-Myers Squibb Company, Caris Life Sciences, Inc., Clarient, Inc., Genentech, Inc., ImClone Systems, Lilly USA, LLC,
Morphotek Inc, Novartis, Pfizer Inc., sanofi-aventis
Speakers’ Bureau
ImClone Systems-Bristol-Myers Squibb Company, Lilly USA, LLC
Advisory Board
YM BioSciences, Inc.
Thomas E. Stinchcombe, MD
Grants/Research Support
Abraxis Bioscience, Bayer HealthCare Pharmaceuticals, Inc., Genentech, Inc.
Speakers’ Bureau
Lilly USA, LLC, Genentech, Inc.
None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.
CME/CE INQUIRIES
For further information, please contact
Educational Concepts Group, LLC
1300 Parkwood Circle SE | Suite 325
Atlanta, Georgia 30339
Phone: 1.770.933.1681 | Fax: 1.770.933.1692
www.educationalconcepts.net
|
